 Atypical antipsychotics have become the drugs of choice in the treatment of schizophrenia as well as acute and maintenance therapy for bipolar disorder. In addition, affective disorders have been found to benefit from these agents Masan 2004. These disorders represent chronic conditions that require extended treatment for years if not lifetimes. In light of the ever widening use of the atypicals, attention must now be focused on adverse reactions that may limit compliance with these agents. Weight gain and sedation have proven to be associated with many atypicals Allison et al. 1999; Wirshing et al. 1999 including clozapine, olanzapine, risperidone and quetiapine. These side effects can reduce compliance and have detrimental effects on patients health over long term treatment. 